Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer

Abstract Triple Negative Breast Cancer (TNBC) accounts for 15–20% of all breast cancer cases, yet is responsible for a disproportionately high percentage of breast cancer mortalities. Thus, there is an urgent need to identify novel biomarkers and therapeutic targets based on the molecular events dri...

Descrición completa

Detalles Bibliográficos

Principais autores:	Kirsten G. M. Aspros, Jodi M. Carter, Tanya L. Hoskin, Vera J. Suman, Malayannan Subramaniam, Michael J. Emch, Zhenqing Ye, Zhifu Sun, Jason P. Sinnwell, Kevin J. Thompson, Xiaojia Tang, Esther P. B. Rodman, Xiyin Wang, Adam W. Nelson, Igor Chernukhin, Feda H. Hamdan, Elizabeth S. Bruinsma, Jason S. Carroll, Martin E. Fernandez-Zapico, Steven A. Johnsen, Krishna R. Kalari, Haojie Huang, Roberto A. Leon-Ferre, Fergus J. Couch, James N. Ingle, Matthew P. Goetz, John R. Hawse
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2022-02-01
Series:	npj Breast Cancer
Acceso en liña:	https://doi.org/10.1038/s41523-022-00387-0
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!